UNLABELLED: Lobeline is a potential smoking cessation drug with affinity for the α4β2 nicotinic acetylcholine receptor and may inhibit the blood-brain barrier (BBB) amine transporter. The goal of this work was to use PET imaging to evaluate the effects of lobeline on the kinetic properties of [(18)F]nifene in the rat brain. METHODS: Direct α4β2* competition of lobeline with [(18)F]nifene was evaluated using imaging experiments with both displacing and blocking doses of lobeline (1mg/kg, i.v.) given between two injections of [(18)F]nifene separated by 50min. Inhibition of the BBB amine transporter was examined using a separate imaging protocol with three injections of [(18)F]nifene, first at baseline, then following (-)nicotine blocking, and finally following lobeline blocking. RESULTS: Rapid displacement of [(18)F]nifene was observed in the α4β2*-rich thalamus following lobeline administration, suggesting direct competition of the drug at α4β2* sites. Slight decreases in BBB transport of [(18)F]nifene were observed when the α4β2* system was first saturated with (-)nicotine and then given lobeline. This perturbation may be due to inhibition of the BBB amine transporter by lobeline or reductions in blood flow. Significant cerebellar displacement of [(18)F]nifene was found following the administration of both lobeline and (-)nicotine, indicating detectable specific binding in the rat cerebellum. CONCLUSION: The competition of lobeline with [(18)F]nifene is largely dominated at the α4β2* binding site and only small perturbations in BBB transport of [(18)F]nifene are seen at the 1mg/kg dose. Similar experiments could be used to study other drugs as therapeutic agents for smoking cessation with PET.
UNLABELLED: Lobeline is a potential smoking cessation drug with affinity for the α4β2 nicotinic acetylcholine receptor and may inhibit the blood-brain barrier (BBB) amine transporter. The goal of this work was to use PET imaging to evaluate the effects of lobeline on the kinetic properties of [(18)F]nifene in the rat brain. METHODS: Direct α4β2* competition of lobeline with [(18)F]nifene was evaluated using imaging experiments with both displacing and blocking doses of lobeline (1mg/kg, i.v.) given between two injections of [(18)F]nifene separated by 50min. Inhibition of the BBB amine transporter was examined using a separate imaging protocol with three injections of [(18)F]nifene, first at baseline, then following (-)nicotine blocking, and finally following lobeline blocking. RESULTS: Rapid displacement of [(18)F]nifene was observed in the α4β2*-rich thalamus following lobeline administration, suggesting direct competition of the drug at α4β2* sites. Slight decreases in BBB transport of [(18)F]nifene were observed when the α4β2* system was first saturated with (-)nicotine and then given lobeline. This perturbation may be due to inhibition of the BBB amine transporter by lobeline or reductions in blood flow. Significant cerebellar displacement of [(18)F]nifene was found following the administration of both lobeline and (-)nicotine, indicating detectable specific binding in the rat cerebellum. CONCLUSION: The competition of lobeline with [(18)F]nifene is largely dominated at the α4β2* binding site and only small perturbations in BBB transport of [(18)F]nifene are seen at the 1mg/kg dose. Similar experiments could be used to study other drugs as therapeutic agents for smoking cessation with PET.
Authors: David D Allen; Paul R Lockman; Karen E Roder; Linda P Dwoskin; Peter A Crooks Journal: J Pharmacol Exp Ther Date: 2003-03 Impact factor: 4.030
Authors: Dennis K Miller; John R Lever; Kelli R Rodvelt; James A Baskett; Matthew J Will; George R Kracke Journal: Drug Alcohol Depend Date: 2007-03-21 Impact factor: 4.492
Authors: Dennis K Miller; Peter A Crooks; Guangrong Zheng; Vladimir P Grinevich; Seth D Norrholm; Linda P Dwoskin Journal: J Pharmacol Exp Ther Date: 2004-04-30 Impact factor: 4.030
Authors: Ansel T Hillmer; Dustin W Wooten; Maxim S Slesarev; Elizabeth O Ahlers; Todd E Barnhart; Dhanabalan Murali; Mary L Schneider; Jogeshwar Mukherjee; Bradley T Christian Journal: J Nucl Med Date: 2012-07-31 Impact factor: 10.057
Authors: R M Kessler; M S Ansari; T de Paulis; D E Schmidt; J A Clanton; H E Smith; R G Manning; D Gillespie; M H Ebert Journal: J Nucl Med Date: 1991-08 Impact factor: 10.057
Authors: Patrick J Lao; Tobey J Betthauser; Dana L Tudorascu; Todd E Barnhart; Ansel T Hillmer; Charles K Stone; Jogeshwar Mukherjee; Bradley T Christian Journal: Synapse Date: 2017-04-26 Impact factor: 2.562
Authors: Ansel T Hillmer; Dustin W Wooten; Mohammed Farhoud; Andrew T Higgins; Patrick J Lao; Todd E Barnhart; Jogeshwar Mukherjee; Bradley T Christian Journal: Synapse Date: 2013-08-30 Impact factor: 2.562
Authors: Ansel T Hillmer; Dustin W Wooten; Maxim S Slesarev; Elizabeth O Ahlers; Todd E Barnhart; Mary L Schneider; Jogeshwar Mukherjee; Bradley T Christian Journal: J Cereb Blood Flow Metab Date: 2013-08-14 Impact factor: 6.200
Authors: Tobey J Betthauser; Ansel T Hillmer; Patrick J Lao; Emily Ehlerding; Jogeshwar Mukherjee; Charles K Stone; Bradley T Christian Journal: Nucl Med Biol Date: 2017-08-17 Impact factor: 2.408